Evolent Health, Inc.

NYSE:EVH

Medical - Healthcare Information Services

Healthcare
$3.93 -6.00%

-$0.28 today

Market cap
$442.05M
Beta
0.83
P/E (TTM)
-1.0
EPS (TTM)
-$4.44
52W Low $2.10High $12.07

Volume 3.10M

Average 2.78M

EVH Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Evolent Health, Inc.NYSE: EVH

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income dips below year-ago levels

Q1 FY2026 net income of $26.63M (cash outflow) fell 58.8% year over year, behind the +384.3% change in trailing-twelve-month net income. Sequentially, it fell 93.8% from the prior quarter. Over 3 fiscal years it compounded at +211.5% a year.

Context

  • Net income amounted to 30.9% of revenue in FY2025, up 28.5 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 10 analysts of $26.3M (+104.5%) for the fiscal year ending Dec 2026, a slowdown from the +840.2% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$26.63M-93.8% QoQ
Last fiscal yearDec 2025
-$579.4M+840.2% YoY
LTMMar 2026
-$527.72M+384.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-58.8%-97.7%-38.9 pp
1 year+840.2%+104.5%-735.7 pp
3-year CAGR+211.5%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(579.4M) USD
Year-over-year change
-840.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How EVH compares with its peers on the latest reported figures

  • EVH's LTM Mar 2026 net income of $527.72M is the largest of the 11 companies compared; the peer median is $120.4M.
  • Its year-over-year change of +384.3% is the highest of 11, against a peer median of +25.5%.
  • Net income amounts to 27.9% of revenue for EVH, versus a peer median of 60.9%.
EVH Competitors Peer median
Net Income for EVH and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EVHEvolent Health, Inc.LTM Mar 2026$527.72M +384.3%+211.5%27.9%
MYGNMyriad Genetics, Inc.LTM Mar 2026$399.9M +294.4%+48.4%48.2%
MGTXMeiraGTx Holdings plcLTM Mar 2026$328.6M +96.4%-4.1%412.0%
REPLReplimune Group, Inc.LTM Dec 2025$314.85M +37.9%+28.0%—
KURAKura Oncology, Inc.LTM Mar 2026$294.57M +62.0%+27.1%411.2%
NUTXNutex Health, Inc.LTM Mar 2026$187.54M +33.9%—21.3%
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$145.24M +14.0%+65.2%—
PSNLPersonalis, Inc.LTM Mar 2026$95.55M +13.7%-10.5%148.1%
BFLYButterfly Network, Inc.LTM Mar 2026$75.77M +17.1%-23.0%73.6%
AMNAMN Healthcare Services, Inc.LTM Mar 2026$32.44M -80.4%—0.9%
HSTMHealthStream, Inc.LTM Mar 2026$19.92M +4.2%+14.9%6.4%
Peer median (excluding EVH) $120.4M+25.5%+21.0%60.9%

Competitors are the stored peer set for EVH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(37.6M)(19.16M)(113.04M)(61.62M)(579.4M)
Depreciation & Amortization60.04M67.2M123.42M125.62M122.65M
Deferred Income Tax(526K)342K(31.27M)(2.82M)(2.98M)
Stock-Based Compensation16.71M33.98M40.5M39.75M39.74M
Change in Working Capital(22.49M)(104.44M)21.89M(116.56M)(57.38M)
Accounts Receivables(24.76M)(102.98M)(164.69M)32.06M73.7M
Inventory00000
Accounts Payables7.25M13.17M(6.72M)4.25M6.64M
Other Working Capital(4.98M)(14.63M)193.31M(152.87M)(137.73M)
Other Non-Cash Items22.62M10.53M101.09M34.4M516.23M
Operating Cash Flow38.75M(11.55M)142.58M18.77M38.84M
Capital Expenditures(24.98M)(38.36M)(28.75M)(24.89M)(34.09M)
Acquisitions (Net)14.22M5.55M870K(30.73M)(57.44M)
Purchases of Investments(3M)(5.55M)0(7.32M)(1M)
Sales of Investments500K5.55M07K986K
Other Investing Activities(2.53M)(226.31M)(387.67M)091.31M
Investing Cash Flow(15.79M)(259.12M)(415.54M)(62.93M)(233K)
Debt Repayment(37.69M)219.74M183.29M58.58M65.06M
Common Stock Issued13.29M4.45M180.52M3.46M0
Common Stock Repurchased0000(40M)
Dividends Paid(1.3M)(14.88M)(18.79M)(20.09M)(11.13M)
Other Financing Activities(3.85M)(77.77M)(63.68M)(42.52M)(49.86M)
Financing Cash Flow(29.55M)131.54M281.34M(565K)(35.92M)
Effect of Forex Changes(52K)(657K)(79K)(229K)11.81M
Net Change in Cash(6.64M)(139.78M)8.3M(44.96M)14.49M
Free Cash Flow13.76M(49.91M)113.84M(6.13M)4.76M

Evolent Health, Inc.

NYSE:EVH

Intrinsic Alpha fair value

Locked

Current Price

$3.93

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.